Immuron CEO to Present at RedChip Global Online Growth Conference
April 23 2018 - 06:57PM
Immuron Limited (ASX:IMC) (NASDAQ:IMRN), Australian microbiome
biopharmaceutical company focused on developing and commercialising
orally delivered targeted polyclonal antibodies for the treatment
of inflammatory mediated and infectious diseases, is pleased to
advise shareholders and investors that CEO Dr Jerry Kanellos, will
be presenting at 10:00 am USET on Wednesday April 24th, 2018 at
this month’s US RedChip Global Online Growth Conference. The
20-minute presentation will be followed by a live Question and
Answer session, to participate visit the Red Chip website.
More than 12,000+ unique viewers participated in
the RedChip Global Online CEO Conferences in
2017.
COMPANY CONTACT: Jerry
KanellosChief Executive Officer (Interim)Ph: +61 (0)3 9824
5254jerrykanellos@immuron.com |
USA
INVESTOR RELATIONS: Jon CunninghamRedChip
Companies, Inc.US Ph: +1 (407) 644 4256, (ext.
107)jon@redchip.com |
AUS
INVESTOR RELATIONS: Peter TaylorNWR
CommunicationsPh: +61 (0)4 1203
6231peter@nwrcommunications.com.au |
ABOUT REDCHIP:RedChip a world
leader in investor relations, financial media, and research for
microcap and small-cap stocks. Founded in 1992, and headquartered
in Orlando, Florida, with affiliates in New York, Pittsburgh,
Paris, and Seoul, RedChip has helped hundreds of companies achieve
their capital markets goals and has been ranked by Inc. Magazine as
one of the fastest growing privately held investor relations firms
in the U.S.
RedChip delivers concrete, measurable results
for its clients through its extensive global network of
institutional and retail stock brokers, RIA's, family offices,
investment banks, hedge funds, and accredited investor groups.
Their unique platform combines traditional investor relations
services with multi-media marketing.
ABOUT IMMURON:Immuron Limited (ASX: IMC,
NASDAQ: IMRN), is an Australian microbiome biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.. Immuron has a unique and safe
technology platform that enables a shorter development therapeutic
cycle. The Company currently markets and sells Travelan® for the
prevention of Travelers’ Diarrhea and its lead clinical candidate,
IMM-124E, is in Phase II clinical trials for Non-Alcoholic
Steatohepatitis (NASH), Severe Alcoholic
Hepatitis (SAH) and Pediatric Nonalcoholic Fatty
Liver Disease (NAFLD). Immuron’s second clinical
stage asset, IMM-529, is targeting Clostridium difficile
Infections (CDI). These products together with the
Company’s other preclinical immunotherapy pipeline products
targeting immune-related diseases currently under development, will
meet a large unmet need in the global immunotherapy
market. For more information visit:
http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited
to, any statements relating to our growth strategy and product
development programs and any other statements that are not
historical facts. Forward-looking statements are based on
management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock value. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to
the timing of starting and completing clinical trials;
uncertainties relating to preclinical and clinical testing; our
dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by
law.
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2023 to Mar 2024